Ophthotech Announces First Patient Dosed in Zimura® Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy, an Advanced Form of Dry Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Complement factor C5 is a central component of the complement cascade believed to be involved in the development of AMD. The Phase 2/3 randomized, double-masked, controlled trial is designed to evaluate the safety and efficacy of Zimura® monotherapy in patients with geographic atrophy. The Company has also recently announced the initiation of a Phase 2 study of Zimura® in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden.
“Dry age-related macular degeneration continues to be a significant unmet medical need globally with no approved treatment options available to patients”
“Dry age-related macular degeneration continues to be a significant unmet medical need globally with no approved treatment options available to patients,” said David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. “Multiple published studies suggest that the complement pathway has a central role in dry AMD. We plan to explore the potential of Zimura® as a treatment for geographic atrophy.
Source: Business Wire